Study characteristics
| Cohorts | Nexposed | Ntotal | RR in ms, mean (SD) | QT in ms, mean (SD) | Age in years, mean (SD) | Females, % | QTdef, % | β-Blockers, % | Verapamil, % | Diltiazem, % |
|---|---|---|---|---|---|---|---|---|---|---|
| European | ||||||||||
| AGES | 67 | 1976 | 938 (153) | 406 (33.6) | 74.6 (4.7) | 64.2 | 3.0 | 13.7 | 1.7 | 3.5 |
| ARIC | 343 | 8132 | 929 (138) | 399 (28.8) | 54.0 (5.7) | 53.0 | 3.4 | 10.2 | 1.8 | 2.0 |
| ASCOT | 167 | 3755 | 877 (153) | – | 63.6 (8.1) | 17.8 | – | 45.1 | 0.3 | 1.5 |
| CHS | 165 | 2893 | 953 (151) | 414 (32.2) | 72.1 (5.2) | 62.8 | 3.3 | 10.8 | 3.4 | 3.3 |
| FHS | 56 | 3168 | 981 (159) | 414 (29.9) | 40.2 (8.8) | 39.5 | 0.3 | 3.5 | NA | NA |
| Health ABC | 43 | 1442 | 952 (153) | 414 (32.3) | 73.7 (2.8) | 49.4 | 3.5 | 13.8 | 3.5 | 5.7 |
| MESA | 55 | 2384 | 977 (149) | 412 (29.3) | 62.3 (10.1) | 52.1 | 0.9 | 7.1 | 0.3 | 0.1 |
| NEO | 84 | 5366 | 940 (150) | 406 (29.3) | 55.9 (5.9) | 47.0 | 1.4 | 12.6 | 0.3 | 0.2 |
| PROSPER | 151 | 4555 | 932 (163) | 414 (36.0) | 75.3 (3.3) | 46.6 | 2.6 | 20.2 | 2.1 | 5.4 |
| RS1 | 85 | 4805 | 875 (148) | 397 (28.8) | 68.8 (8.6) | 60.2 | 2.6 | 15.3 | 0.7 | 1.6 |
| RS2 | 31 | 1889 | 886 (140) | 406 (28.6) | 65.0 (7.6) | 56.6 | 2.3 | 15.5 | 0.3 | 1.2 |
| RS3 | 23 | 1950 | 881 (131) | 401 (26.0) | 56.0 (5.7) | 54.1 | 1.1 | 10.5 | 0.1 | 0.4 |
| WHI GARNET | 60 | 1391 | 928 (139) | 401 (30.3) | 65.0 (6.8) | 100.0 | 1.4 | 11.4 | 2.4 | 2.1 |
| WHI MOPMAP | 87 | 2000 | 929 (135) | 402 (30.1) | 63.0 (6.6) | 100.0 | 0.9 | 13.3 | 1.9 | 1.9 |
| Summary | 1417 | 45 706 | 875-981 | 397–414 | 40.2–75.3 | 17.8–100 | 0.3–3.5 | 3.5–45.1 | 0.3–3.5 | 0.1–5.7 |
| African-Americans | ||||||||||
| ARIC | 114 | 2191 | 927 (151) | 400 (32.8) | 53.0 (5.8) | 62.4 | 2.8 | 9.8 | 3.5 | 1.7 |
| CHS | 24 | 707 | 921 (166) | 409 (35.3) | 72.6 (5.6) | 64.6 | 2.9 | 11.2 | 5.8 | 6.2 |
| Health ABC | 24 | 1014 | 932 (143) | 411 (34.8) | 73.4 (2.9) | 57.6 | 3.1 | 10.1 | 5.9 | 6.3 |
| JHS | 35 | 2096 | 948 (150) | 411 (30.1) | 49.5 (11.8) | 60.5 | 1.3 | 8.6 | 2.7 | 3.1 |
| WHI CT SHARe | 98 | 4227 | 921 (149) | 401 (33.8) | 61.0 (6.8) | 100.0 | 1.3 | 11.7 | 4.8 | 4.0 |
| Summary | 295 | 10 235 | 921–948 | 400–411 | 49.5–73.4 | 57.6–100 | 1.3–3.1 | 8.6–11.7 | 2.7–5.9 | 1.7–6.3 |
| Hispanic/Latinos | ||||||||||
| WHI CT SHARe | 41 | 1784 | 928 (133) | 402 (29.7) | 60.0 (6.4) | 100.0 | 1.0 | 8.2 | 2.5 | 1.8 |
| HCHS/SOL | 133 | 12 024 | 975 (143) | 416 (28.4) | 45.7 (13.8) | 59.5 | 0.7 | 6.4 | 0.4 | 0.3 |
| Summary | 174 | 13 808 | 928–975 | 402–416 | 45.7–60.0 | 59.5–100 | 0.7–1.0 | 6.4–8.2 | 0.4–2.5 | 0.3–1.8 |
| Total summary | 1886 | 69 749 | 875–981 | 397–416 | 40.2–75.3 | 17.8–100 | 0.3–3.5 | 3.5–45.1 | 0.3–5.9 | 0.1–6.3 |
AGES, Age, Gene/Environment Susceptibility—Reykjavik Study; ARIC, Atherosclerosis Risk in Communities Study; ASCOT, Anglo-Scandinavian Cardiac Outcomes Trial; CHS, Cardiovascular Health Study; FHS, Framingham Heart Study; GARNET, Genome-wide Association Research Network into Effects of Treatment; HCHS/SOL, Hispanic Community Health Study/Study of Latinos; Health ABC, Health, Aging and Body Composition Study; JHS, Jackson Heart Study; MESA, Multi-Ethnic Study of Atherosclerosis; MOPMAP, Modification of Particulate Matter-Mediated Arrhythmogenesis in Populations; NA, not available. NEO, Netherlands Epidemiology of Obesity; Nexposed, number of participants using tricyclic antidepressants; Ntotal, total number of participants contributing in the analysis; PROSPER, Prospective Study of Pravastatin in the Elderly at Risk; RS, Rotterdam Study; SHARe, Single nucleotide polymorphism (SNP) Health Association Resource project; WHI CT, Women's Health Initiative Clinical Trials.